RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Royalty Pharma plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income from financial royalty assets | $2.40B | $2.32B | $2.26B | $2.23B | $2.18B | $2.15B | $2.15B | $2.11B | $2.09B | $2.07B | $2.20B | $2.22B | 94.8% | +10.0% |
| Other royalty income and revenues | $131.74M | $123.87M | $117.04M | $119.28M | $120.32M | $116.48M | $114.15M | $155.36M | $151.49M | $163.95M | $156.80M | $140.20M | 5.2% | +9.5% |
| Revenue from intangible royalty assets | – | – | – | – | – | – | – | – | – | – | $835.00K | $885.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Royalty Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.